Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
0.981
-0.005 (-0.49%)
At close: Dec 20, 2024, 4:00 PM
0.980
-0.001 (-0.11%)
After-hours: Dec 20, 2024, 4:40 PM EST
Achilles Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Buy
Price Target
$4.00
Upside
+307.71%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +103.85% | Apr 5, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $6 | Strong Buy | Maintains | $11 → $6 | +511.56% | Apr 5, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $0.5 | Strong Buy → Sell | Downgrades | $7 → $0.5 | -49.04% | Dec 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +1,021.19% | Aug 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +1,021.19% | May 11, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +1,632.75% | Dec 7, 2022 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +715.41% | Dec 7, 2022 |
| JP Morgan | JP Morgan | Sell Initiates $11 | Sell | Initiates | $11 | +1,021.19% | Apr 26, 2021 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +2,652.01% | Apr 26, 2021 |
| Piper Sandler | Piper Sandler | Buy Initiates $25 | Buy | Initiates | $25 | +2,448.16% | Apr 26, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +2,244.31% | Apr 26, 2021 |